Advertisement
"MaxCyte is pleased to have this opportunity to support SMi and the pharmaceutical industry in technical discussions on state of the art techniques and methods for the successful development of cell-based assays," says Dr. Madhusudan Peshwa, Vice President of Research and Development at MaxCyte. "We believe that the MaxCyte(R) STX addresses many of the technical challenges facing researchers today, including reducing the time and expense needed to develop assays for high throughput screening. The MaxCyte(R) STX System enables the small and large scale transfection of primary cells, cell lines, and stem cells with single and multiple loading agents at the same time. About 10 billion cells can be transfected in less than 30 minutes. The MaxCyte STX can be a useful tool for biopharmaceutical companies to develop more relevant screening systems, which can increase the likelihood of finding successful drug candidates."
Advertisement
According to MaxCyte CEO Doug Doerfler, "We are very pleased to announce the European launch of the MaxCyte(R) STX System. The MaxCyte STX is being viewed by the pharmaceutical industry as an enabling technology for cell modification for both research and larger scale cell-based applications in drug discovery. The ability of the system to operate effectively at any scale, with any molecule and with any cell, can significantly reduce bottlenecks and improve the productivity of drug discovery groups. The power of our technology -- its speed, throughput, consistency, and efficiency in a closed, sterile, non-toxic environment -- naturally translates into solving a major issue in the drug discovery sector: the rapid and cost effective development of cell-based assays to validate targets and conduct high throughput screens."
Scientists from MaxCyte will be available at the SMi conference for discussions on the MaxCyte STX Scalable Transfection System technology and its applications.
About MaxCyte
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy, MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte STX Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.
For more information, www.maxcyte.com
SOURCE MaxCyte, Inc.
